FF EAI Robotics Ecosystem Inc.
Close on Oct 19, 2026
- Market cap
- $21.71M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | After market close | – | $-0.21 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 15, 2023 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 16, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 13, 2022 | Before market open | – | – | – |
| Q4 FY2018 Ended Dec 31, 2018 | Mar 29, 2019 | Before market open | – | – | – |
| Q3 FY2018 Ended Sep 30, 2018 | Nov 9, 2018 | Before market open | – | – | – |
| Q2 FY2018 Ended Jun 30, 2018 | Aug 15, 2018 | After market close | – | – | – |
| Q1 FY2018 Ended Mar 31, 2018 | May 15, 2018 | After market close | – | – | – |
| Q4 FY2017 Ended Dec 31, 2017 | Mar 19, 2018 | Before market open | – | – | – |
| Q4 FY2016 Ended Dec 31, 2016 | Feb 27, 2017 | During market hours | – | – | – |
Company guidance
Outlook given with results on Mar 27, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| monthly active users (MAU) across the AIxC ecosystem | year-end | 100,000 | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements FF EAI Robotics Ecosystem filed with the SEC
EAI Robotics Ecosystem Signs Definitive Agreements to Combine FFAI’s Full Robotics Business at About $200 Million and $2.246 Per
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Announces Strategic Pivot to Physical AI and Robotic Operations Commercialization; RoboShare Completes First Paid Commercial Order
Regulation FD disclosure · EX-99.1 to Form 8-K
Holdings Reports Second Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Holdings Reports First Quarter 2026 Results; Highlights Q1 Execution Across Embodied AI, RWA Tokenization, and AI Agent Platforms
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Holdings Reports Full Year 2025 Financial Results; Highlights Transformational Pivot to AI and Blockchain Infrastructure
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ANGELES, Feb. 23, 2026 /PRNewswire/ — AIxCrypto Inc. (NASDAQ: AIXC) (“AIxC” or the “Company”), a
Other events · EX-99.1 to Form 8-K
Los Angeles, CA (Feb 2, 2026)
Material agreement · Other events · EX-99.1 to Form 8-K
to Advance Tokenization Strategy with Proposed Strategic Investment in Faraday Future
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its “Three Driving Forces” Strategy to Become the No.1 Gateway
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Qualigen Therapeutics Stockholders Approve All Proposals
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE Transaction
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Effect to the June 2025 Private Placement and the Amended Note)
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Therapeutics Provides Update on Nasdaq Communications
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Effect to the July 2025 Private Placement of Series A-3 Preferred Stock)
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Granted New Patents Covering 25 Countries
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
to participate in next funding round for NanoSynex
Regulation FD disclosure · EX-99.1 to Form 8-K
Expected to Begin Trading on Split-Adjusted Basis on November 5 , 2024
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
Other events · EX-99.1 to Form 8-K
Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
Listing notice · Other events · EX-99.1 to Form 8-K
Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics Divests FastPack ® Diagnostics Business
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Pro Forma Condensed Consolidated Financial Information
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K